# US 2014/0155470 A1 · Pla2r1 as anti-tumoral compound and as biomarker for the detection of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155470 A1 - Document ID: US20140155470A1 - Status: Published application - Kind: A1 - Application number: 14/131,267 - Filed: 2012-07-06 - Published: 2014-06-05 - Earliest claimed: 2011-07-08 - Inventors: David Bernard; Arnaud Augert; Gerard Lambeau; Christophe Girard; David Vindrieux - Web page: https://patentgrep.com/patent/US20140155470A1 ## CPC - A61K 38/178: {Lectin superfamily, e.g. selectins} - C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} - C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72} - C12Y 301/01004: Phospholipase A2 (3.1.1.4) - G01N 33/57515: of the breast - G01N 33/57525: of the liver or pancreas - G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12Y: ENZYMES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Compositions comprising a polynucleotide of human PLA2R1, a polypeptide of human PLA2R1 or an extracellular fragment of human PLA2R1 for use in the treatment of cancer in particular breast cancer, pancreatic cancer, colorectal cancer, kidney cancer and melanoma. ## Claims ### Claim 1 A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a composition comprising a polynucleotide selected from the group consisting of: The polynucleotide of SEQ ID NO. 1 or a variant thereof having at least 95% identity with the sequence of SEQ ID No. 1; A polynucleotide encoding the human PLA2R1 polypeptide of SEQ ID NO. 2 or encoding a variant thereof having at least 95% identity with the sequence of SEQ ID No. 2; A polynucleotide from position 1 to position 4191 of SEQ ID NO.1 encoding the extracellular domain of human PLA2R1 or a variant thereof having at least 95% identity with the polynucleotide from position 1 to position 4191 of SEQ ID NO.1; A fragment of the polynucleotide from position 1 to position 4191 of SEQ ID NO.1 encoding a fragment of the extracellular domain of PLA2R1 or a variant thereof having at least 95% identity with a fragment of the polynucleotide from position 1 to position 4191 of SEQ ID NO.1; and A polynucleotide encoding a polypeptide of SEQ ID NO. 4, 6 or 8. ### Claim 2 (depends on 1) The method of claim 1 wherein the fragment of the polynucleotide from position 1 to position 4191 of SEQ ID NO.1 encodes at least the Cys-rich domain, the fibronectin type II domain and a C-type lectin domain of human PLA2R1. ### Claim 3 (depends on 1) The method of claim 1 wherein the fragment of the polynucleotide from position 1 to position 4191 of SEQ ID NO.1 is selected from the group consisting of the polynucleotides of SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7 and variants thereof having at least 95% identity with the polynucleotide of SEQ ID NO. 3, SEQ ID NO.5 or SEQ ID NO.7. ### Claim 4 (depends on 1) The method of claim 1 wherein said polynucleotide is inserted in a viral vector. ### Claim 5 (depends on 1) The method of claim 1 wherein said polynucleotide is incorporated in a delivery vehicle. ### Claim 6 A method for treating cancer in a patient in need thereof, comprising administering to said patient an effective amount of a composition comprising a polypeptide selected from the group consisting of: The Human PLA2R1 polypeptide depicted in SEQ ID NO. 2 or a variant thereof having at least 95% identity with the polypeptide of SEQ ID No. 2; The extracellular domain of human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2 or a variant thereof having at least 95% identity with the human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2; and A fragment of the extracellular domain of human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2 or a variant thereof having at least 95% identity with a fragment the human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2. ### Claim 7 (depends on 6) The method of claim 6 wherein the fragment of the extracellular domain of human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2 comprises at least the Cys-rich domain, the fibronectin type II domain and a C-type lectin domain of human PLA2R1. ### Claim 8 (depends on 6) The method of claim 6 wherein the fragment of the extracellular domain of human PLA2R1 polypeptide from position 21 to position 1397 of SEQ ID NO.2 is selected from the group consisting of the polypeptide from position 21 to position 1322 of SEQ ID NO. 4, the polypeptide from position 21 to position 1098 of SEQ ID NO. 6, the polypeptide from position 21 to position 645 of SEQ ID NO. 7 and variants thereof having at least 95% identity with the polypeptide from position 21 to position 1322 of SEQ ID NO. 4, at least 95% identity with the polypeptide from position 21 to position 1098 of SEQ ID NO. 6 or at least 95% identity with the polypeptide from position 21 to position 645 of SEQ ID NO. 8. ### Claim 9 (depends on 1) The method of claim 1 wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, colorectal cancer and melanoma. ### Claim 10 A polypeptide encoding a soluble extracellular fragment of human PLA2R1 comprising the polypeptide of SEQ ID NOs. 4, 6, 8 or variants thereof having at least 95% identity with the polypeptide of SEQ ID NO. 4, at least 95% identity with the polypeptide of SEQ ID NO. 6 or at least 95% identity with the polypeptide of SEQ ID NO. 8. ### Claim 11 (canceled) ### Claim 12 (depends on 10) Polynucleotide encoding a polypeptide according to claim 10. ### Claim 13 (canceled) ### Claim 14 (canceled) ### Claim 15 (canceled) ### Claim 16 (depends on 6) The method of claim 6 wherein the cancer is selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, colorectal cancer and melanoma.